JNJ Johnson & Johnson

bullish track record → $225.33 -5.47 (-2.4%)
Mkt Cap $564B P/E 27.2 fwd 18.4 52wk $149.04 - $251.71 7d ago
Est. revisions: +0.4% (5 up, 11 down in 30d)
Factor Model (net -1.0)

Factor Model

net -1.0 2.7 / 10
Est. Revisions
+0.0
Insider Activity
+0.0
Momentum
-0.1
Analyst Rev.
-0.6
Narrative Gap
+0.0

JNJ gains with fresh drug approvals

Watch: Watch upcoming earnings and new drug launch progress for signs of sustained growth and margin resilience.

Johnson & Johnson secured multiple approvals including ICOTYDE for plaque psoriasis, TECVAYLI with DARZALEX FASPRO for multiple myeloma, VARIPULSE Pro in Europe, and TECNIS PureSee for U.S. cataracts. Phase 2b data for JNJ-4804 in inflammatory bowel disease was positive as of May 5, 2026. The company operates amid decelerating revenue momentum but solid 9.9% revenue growth and strong analyst bullishness.

These new approvals represent pipeline strength that supports Johnson & Johnson's defensive growth case and underpins its ongoing revenue and earnings potential amid a challenging macro environment.

Evidence

3d ago Is Johnson & Johnson Stock Outperforming the Dow? yahoo-finance
8d ago Why Johnson & Johnson (JNJ) Still Fits a Defensive Growth Case yahoo-finance
11d ago Trump declares the end of America’s ‘economic surrender’ — blasts ‘gutless’ leaders for crushing US prosperity yahoo-finance
13d ago Meet the Dividend King With a Higher Credit Rating Than the U.S. Government yahoo-finance
14d ago Kiplinger’s May 2026 Letter Says Yields From 3% to 13% Are Available Right Now Despite Iran War Uncertainty yahoo-finance
19d ago Leerink Partners up JNJ: Market Perform → Outperform
23d ago A $500,000 Dividend Portfolio That Pays More Than a Full-Time Minimum Wage Job yahoo-finance
28d ago Jim Cramer Believes Competitors Might Hurt Intuitive Surgical yahoo-finance
7 older signals
28d ago Factbox-Global drugmakers rush to boost US presence as tariff threat looms
28d ago Johnson & Johnson’s (JNJ) Accelerating Growth Justifies the Higher Multiple
31d ago Jim Cramer Says “You’ve Got a Winner in CCJ”
31d ago Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering
31d ago S&P 500's Best‑Kept Secret: Why Healthcare Could Be 2026's Breakout Winner
34d ago Jim Cramer says health care is the 'cold' hedge your AI-heavy portfolio is missing — and shares 4 stocks to consider
34d ago Johnson & Johnson AGM: CEO Duato touts “catalyst year,” 5.3% sales growth and $32B investment push
Fundamentals & Data ▾
Johnson & Johnson Healthcare · Drug Manufacturers - General
Mkt Cap
$564B
P/E
27.2 fwd 18.4
Beta
0.26
Div Yield
229.00%
52w Range
$149.04 - $251.71
Short Interest
22.3M 1.03%
Days to Cover
2.9 +0%
Technicals mixed
vs 20d MA
+1.5%
vs 50d MA
-0.8%
from 52w Hi
-5.9%
Vol (20d)
18%
1w return
+1.2%
1m return
+1.3%
Vol ratio
0.8x
Insiders
selling 1B / 4S
Analysts
bullish 1 up / 0 down
EPS Estimate
$2.85 +0.4% 30d 5up / 11dn
Est. Dispersion
12% 17 analysts
Analyst Target
$253 $155 - $285
Options P/C
0.13
Fund Convergence
strong D.E. Shaw, Citadel, Bridgewater, Two Sigma
Financials
Revenue
$24.1B +10% YoY
FCF
$1.5B
Gross Margin
66%
Op Margin
27%
Momentum: decelerating
Top Holders
D.E. Shaw $4.8B
Citadel $1.3B
Bridgewater $272M
Two Sigma $73M
Recent Filings & Data
analyst rating 1
Leerink Partners up → Outperform 19d ago
15 signals · latest 3d ago

Keep reading the market

Direction shifts, insider clusters, filing red flags, and earnings call changes stay published on the site.

All stocks → Track record → How it works →